



ZKB London Roadshow 2024

Cicor Technologies Ltd.

July 3, 2024



Disclaimer

The information in this presentation does not constitute an offer or invitation and may not be construed as a recommendation by us to purchase, hold or sell shares of Cicor Technologies Ltd.

This information or any copy thereof may not be sent or taken to or distributed in any jurisdiction in which such transmission or distribution is unlawful. This document may contain certain 'forward-looking' statements. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances. Actual outcomes and results may differ materially from any outcomes or results expressed or implied by such forward-looking statements.

The Cicor Group

Turning ideas into advanced electronic solutions


Medical



25% of pro forma sales 2024

Cicor helps improve global healthcare by the development and manufacture of applications such as hearing aids, surgical robots or smart drug delivery systems

Industrial



37% of pro forma sales 2024

Cicor is at the forefront of technology, driving miniaturization and automation in areas such as robotics, sensors, control systems and semi-conductor equipment

Aerospace & Defence (A&D)



23% of pro forma sales 2024

Solutions from Cicor in aircrafts, satellites and defense systems **ensure safety, reliability and communication** at land, sea, in the skies and beyond

Facts and figures

Sales growth

24.5% to CHF 390m

Organic growth of 11.1%, gaining market share

Sales to strategic markets

84%

Strengthened focus on Industrial, Medical, Aerospace & Defence

19

Sites, resilient setup in Europe and Asia (May 2024)

EBITDA margin

11.6%

Top profitability amongst peers

Book-to-bill rate

1.03

Despite a recessionary environment

3,250

Employees worldwide, of which 10% with engineering degree (May 2024)



One stop shop – creating strategic partnerships with customers



Close to customers and competitive



Building of leading platforms in attractive markets

European market leader for A&D EMS



- Long-standing supplier of design and manufacturing services to 30 leading A&D integrators in Europe
- True one-stop shop from systems engineering, critical components, assembly, on-site support and training
- Acquisition of Axis Electronics (completed 11/2021), STS Defence (01/2024) and TT Electronics' IoT division (03/2024) turned Cicor into the European leader for A&D electronics

CAGR 2021-2023

66%

Share of PF sales 2024

23%

Market position Europe

No. 1



Cicor's Domain Expertise

Communications and Networks

- Secure networks
- Satellite communications
- Antennas and RF
- Messaging Command and Control
- Information Assurance

For the Royal Navy's future Type 26, City class frigate, Cicor designed twin configurable masts for communications and sensor antennas.



Electronic Warfare

- Advanced signal processing
- Electronic Support Measures
- Calibration
- Countermeasures


Cicor designs and manufactures high-reliability cable sets for portable targeting systems that withstand the harshest environments.



Control and Instrumentation

- Control systems
- Engine management
- Databus networks
- Power distribution
- Rugged consoles, enclosures & racks

NASA's Perseverance rover is discovering Mars using memory modules that contain Cicor-manufactured PCBs.



Building of leading platforms in attractive markets

Advancing healthcare through technology



- CDMO for medical devices supporting people to live healthier lives
- True one-stop shop from device engineering to critical component development/manufacturing and assembly
- Enabling advanced healthcare through miniaturization, bio-compatibility, printed electronics
- Serving high-growth verticals such as smart drug delivery, robot surgery, neurostimulation

CAGR 2021-2023

31%

Share of PF sales 2024

25%


Market position Europe

No. 4



M&A Update

A strong platform for organic growth and industry consolidation



Focus on our three **core markets** with highly profitable high-mix/low-volume businesses



Strategic customer relationships through excellent solution finding, differentiated technology portfolio and flawless execution



Active consolidation through **M&A**

The EMS market is a highly fragmented and growing market, predestined for consolidation through M&A

Highly fragmented market



- **1.700 EMS companies** in Europe (thereof many smaller owner-led EMS companies looking for succession options).
- Top 10 companies representing **only 40%** of the total market.
- To date, **no clear winners** or players with clear leadership position.

Source: Weiss Engineering (in4ma), 2024

Large, growing market



- EMEA's EMS market has a size of **EUR 57bn** (2023) and a forecasted CAGR of 6.8% until 2030.
- Cicor's core segments (**Medical, Aerospace & Defence & High End Industrial**) represent around **40%** of EMS market.

Source: Weiss Engineering (in4ma), 2023, 2024

High customer loyalty



- Cicor operates in markets with high customer loyalty.
- **High entry barriers** for competitors in **mission-critical applications** through engineering partnerships, validation cycles and government regulations.
- High mix / low volume EMS players with a **history of consistently higher margins** than commoditized low mix / high volume segments.

Clear economies of scale




- Clear **economies of scale** and **competitive advantages** of larger players.
- **High synergy potential** in terms of revenue, cost savings and cash benefits.
- Customers are actively searching for a **consolidated and reliable supply base**.

Long-term market development


A consolidated market with significantly increased profitability of the leading EMS players

Cicor follows a value-accretive buy-and-build strategy since 2021



Note: Dates in timeline refer for acquisitions to month as of when companies were/will be included in Cicor consolidation scope

Profitable growth accelerated since 2022



* The chart shows the mid-points of the guidance 2024. Cicor expects in 2024 sales to grow to CHF 460-500 Million with an EBITDA margin in the target range of 10-13%.

** Net profit (CHF 11.8 million) excluding FX losses (CHF 4.1 million) and one-off tax impacts (CHF 2.7 million) divided by outstanding shares including MCN shares (4'428'767).

Key success factors

- Value-accretive buy-and-build strategy
- Organic sales growth above market growth
- Focus on business excellence driving margins
- Superior profitability of the target sectors Aerospace & Defence, Medical and Industrial

Robust EPS development

- Underlying 2023 net earnings per share** at CHF 4.19

Acquisition of STS Defence Limited



has acquired 100% of the shares of the UK based STS Defence Limited (completed January 24, 2024)



Tech & engineering provider of sustainment, support and modernization solutions for mission-critical electronics and communications systems

Key facts

Location: Gosport, UK (120km south of London)

FTE: 150

Financials: GBP 27.5M of sales (FY 2023) with strong operating margins

Customers: medium to large customers within Aerospace & Defence and other industries located primarily in the UK market

Acquisition rationale

Expand Cicor's platform for the UK market combined with the other announced UK-based acquisitions (i.e., Axis Electronics and two of the three acquired TT Electronics businesses)

Increase Cicor's **capabilities within mission-critical electronics** for the Aerospace and Defence industry

Product examples



Design of Type 26 communication masts

Development of an AI-based, marine engine health monitoring system



Box build and cabling of CERN power systems

Acquisition of Evolution Medtec Srl



has acquired 100% of the shares of the Romanian engineering company Evolution Medtec Srl (completed February 28, 2024)



End-to-end engineering services provider, focused on medical and paramedical applications

Key facts

Location: Bucharest, Romania

FTE: 25

Sales: in the lower single-digits million Euro range for FY 2023

EBITDA: margin comparable to Cicor in FY 2023

Customers: medium and large medical device and industrial companies in Europe, the UK, and the US

Acquisition rationale

Enhancing Cicor's **product development capabilities** in the medical technology sector

Geographic fit: proximity to Cicor's Arad production site and geographic distribution of customers

Product engineering examples



Therapy devices



Class III remote control system and control app



Biometric monitor



Implants



Acoustics

Carve-out of three manufacturing sites from TT Electronics



has acquired 100% of the shares of
TT Electronics IoT Solutions Ltd,
with three businesses
in the UK and China
(completed March 31, 2024)

Carve-out from



*PCBA and box builds for IoT
solutions and OEMs in highly
regulated markets including
full life cycle EMS services and
substantial testing capabilities*

Key facts

Locations: Hartlepool, UK; Newport, UK;
Dongguan, China

FTE: 500

Purchase consideration (EV): GBP 20.8 mln

Sales: GBP 70.2 mln (FY 2023)

Customers: customer base across mission-
critical, high growth sectors including Aerospace
& Defence, Industrial, Green Energy

Acquisition rationale

**Improved business continuity and
expanded capacity** with multiple EMS
production facilities in the UK

Platform for Cicor UK to enter into new
sectors (Industrial, Medical)

Integration of production site in Dongguan,
China, into Cicor Asia

Production sites

25'000 sq.m of manufacturing space



Hartlepool (UK)



Dongguan (China)


IoT Solutions



Cardiff (UK)

**Solutions for OEMs in highly
regulated markets**

Cicor's unique position to create value through M&A



Financial Results FY 2023

Offset Goodwill in Equity

- The Board of Directors of Cicor has decided that goodwill from acquisitions will be offset directly against shareholders' equity at the time of acquisition²⁾
- Previously goodwill was capitalized and amortized over its estimated useful life of five years
- The prior year financial information was restated
- Core results (excluding the amortization of goodwill and intangible assets from acquisitions) will no longer be reported
- The impact of the restatement is shown in the adjacent table

in CHF million	June 2023 (6 months)			December 2023 (12 months)		
	reported	change	restated	reported	change	restated
Goodwill	20.2	-20.2	0.0	16.6	-16.6	0.0
Other intangible assets	35.7	0.0	35.7	31.9	0.0	31.9
Other assets	348.8	0.0	348.8	312.7	0.0	312.7
Total assets	404.7	-20.2	384.5	361.1	-16.6	344.5
Total liabilities	250.9	0.0	250.9	213.0	0.0	213.0
Total equity	153.8	-20.2	133.6	148.1	-16.6	131.5
Total equity and liabilities	404.7	-20.2	384.5	361.1	-16.6	344.5

Net sales	199.2	0.0	199.2	389.9	0.0	389.9
Operating costs	-177.8	0.0	-177.8	-344.8	0.0	-344.8
EBITDA	21.3	0.0	21.3	45.1	0.0	45.1
Depreciation	-5.8	0.0	-5.8	-11.7	0.0	-11.7
Amortization Goodwill	-2.8	2.8	0.0	-5.7	5.7	0.0
Amortization other intangible assets	-2.2	0.0	-2.2	-4.4	0.0	-4.4
Operating profit (EBIT)	10.5	2.8	13.4	23.4	5.7	29.0
Interest and taxes	-5.6	0.0	-5.6	-17.3	0.0	-17.3
Net profit	4.9	2.8	7.7	6.1	5.7	11.8

EBITDA margin	10.7%	0.0%	10.7%	11.6%	0.0%	11.6%
EBIT margin	5.3%	1.4%	6.7%	6.0%	1.5%	7.4%
Net profit margin	2.5%	1.4%	3.9%	1.6%	1.5%	3.0%
Equity Ratio	38.0%	-3.3%	34.8%	41.0%	-2.8%	38.2%
Net debt	-63.0	0.0	-63.0	-43.5	0.0	-43.5
Earnings per share in CHF ¹⁾	1.10	0.64	1.74	1.37	1.28	2.66


1) Earnings per share is calculated considering the 1'267'116 conditional shares that will be created upon conversion of the mandatory convertible notes by January 2027.

2) Link to the media release:

<https://www.cicor.com/en/news/article/cicor-changes-the-accounting-policy-for-the-treatment-of-goodwill/>

Long-term view – Impact of Cicor growth strategy

Cicor Group




Group in TCHF	FY 2022	FY 2023	% YoY
Sales	313 193	389 890	24.5%
EBITDA	32 274	45 135	39.8%
ROS%	10.3%	11.6%	+130 bps

■ Sales H2
 ■ Sales H1
 —●— EBITDA margin in %

- Change in sales at reported FX rates +24.5% (at constant FX rates +27.5%)
- Organic sales growth of 11.1%¹⁾
- Profitable growth with 9.5% Sales CAGR and 12.9% EBITDA CAGR over the last five years.
- STS closed in January 2024, no impact on 2023 results or balance sheet.

1) Change in local currencies, adjusted for acquisitions


Record sales and core results from organic growth and acquisitions



1) Cicor has changed its accounting policy effective 1.1.2024 to offset Goodwill in equity at the time of acquisition with no amortization in future periods. All prior periods have been restated.


Performance 2018 – 2023

Cicor Group




Group in TCHF	FY 2022	FY 2023	%YoY
Sales	313 193	389 890	24.5%
EBITDA	32 274	45 135	39.8%
ROS%	10.3%	11.6%	+130bps

EMS Division



EMS in TCHF	FY 2022	FY 2023	%YoY
Sales	269 637	347 932	29.0%
EBITDA	28 950	43 366	49.8%
ROS%	10.7%	12.5%	+170bps

AS Division



AS in TCHF	FY 2022	FY 2023	%YoY
Sales	44 779	43 011	-3.9%
EBITDA	6 459	6 063	-6.1%
ROS%	14.4%	14.1%	-30bps

Sales H2 Sales H1 EBITDA margin in %

Consolidated Income Statement


	2023	in %	2022	in %	%YoY
Net sales	389 890	100.0	313 193	100.0	24.5
Material expenses	-207 150	-53.1	-167 077	-53.3	24.0
Operating expenses	-137 605	-35.3	-113 842	-36.3	20.9
EBITDA	45 135	11.6	32 274	10.3	39.8
Depreciation	-11 686	-3.0	-10 365	-3.3	12.7
Amortization	-4 404	-1.1	-4 317	-1.4	2.0
EBIT	29 045	7.4	17 592	5.6	65.1
Financial result	-8 362	-2.1	-4 541	-1.4	84.1
Income taxes	-8 923	-2.3	-3 873	-1.2	130.4
Net profit	11 760	3.0	9 178	2.9	28.1

Cicor has changed its accounting policy effective 1.1.2024 to offset Goodwill in equity at the time of acquisition with no amortization in future periods. All prior periods have been restated.

- Record high in Net sales and EBITDA
- Strong contribution from EMS division and economies of scale results in increased overall EBITDA margin of 11.6% (plus 130bps).
- Financial result affected by negative currency effects in both periods, in 2023 the FX effects were MCHF 3 higher than PY.
- Increase in tax rate to 43.1% mainly due to external tax effects, as tax-rate increased in UK and change of tax-scheme in Romania (minimal tax).
- EBIT margin increased to 7.4% driven by improved operating profitability.

FY 2023 in CHF mio

Sales contribution



- Strong organic sales growth in EMS division and good contribution from newly acquired companies.
- Negative currency impact of -3.0% (CHF -9.4 mio) mainly due to the devaluation of GBP, RON and EUR vs. CHF.
- Organic growth includes a decrease in broker sales (low margin sales), this understates EMS organic growth.

Consolidated Balance Sheet

	2023	in %	2022	in %
Current assets	251'896	73.1	251'422	72.9
Non-current assets	92'626	26.9	93'497	27.1
Total Assets	344'522	100.0	344'919	100.0
Current liabilities	114'989	33.4	102'829	29.8
Non-current liabilities	98'044	28.5	115'015	33.3
Equity	131'489	38.2	127'075	36.8
Total Liabilities and equity	344'522	100.0	344'919	100.0
Net Debt	43'484		44'522	
Gearing ratio (net debt in % of equity)	33.1		35.0	
Net debt / EBITDA LTM	0.96		1.38	
Net debt / EBITDA LTM proforma ¹⁾	0.96		1.36	
Equity Ratio	38.2%		36.8%	

1) Acquisitions are included for twelve months pro forma as defined in the covenants agreed with the banking syndicate.

Cicor has changed its accounting policy effective 1.1.2024 to offset Goodwill in equity at the time of acquisition with no amortization in future periods. All prior periods have been restated.

- Focus on ONWC and optimization of treasury activities delivering strong 2023 results. Despite revenue growth of 24.5% balance sheet size slightly reduced demonstrating improved capital efficiency.
- All bank covenants met as of December 2023 (equity ratio > 30.0% and leverage net debt / EBITDA < 3.5 including acquisition pro forma).
- Net debt of CHF 43.5 million decreased by CHF 1.0 million despite investments in two acquisitions in 2023.


Consolidated Cash Flow Statement

	2023	2022
Net profit	11 760	9 178
Depreciation, amortization and impairment	16 090	14 682
Other non cash items	8 371	- 877
Changes in working capital	2 537	-33 040
Net cash from / (used in) operating activities	38 757	-10 057
Purchase of Property, plant and equipment (net)	-12 156	-11 174
Purchase of intangible assets	- 347	- 225
Acquisition of subsidiaries, net of cash acquired	-21 985	-19 645
Net cash used in investing activities	-34 488	-31 044
Free cash flow	4 269	-41 101
Free Cash Flow excl. acquisitions	26 254	-21 456
Net cash from financing activities	-20 578	48 947
Currency translation effects	-1 331	-1 152
Cash flow	-17 640	6 694

- Positive cash flow from operating activities driven by strong net income performance and focus on working capital management.
- Focus on working capital and normalization of supply chain resulted in a positive cashflow
- Positive free cash flow before acquisitions demonstrates value creation of Cicor's core business.

Cicor has changed its accounting policy effective 1.1.2024 to offset Goodwill in equity at the time of acquisition with no amortization in future periods. All prior periods have been restated.

Operating Net Working Capital




1) Acquisitions are included for full twelve months pro-forma

2) Operating NWC: Operating inventory + operating accounts receivable – operating trade payables

- Stabilization in half year 2023 turned into a decrease in second half of 2023, as a result of strong management focus on working capital management.
- Increase in ONWC from recent acquisitions is main driver for increase.
- The improvement to 30% of sales confirms Cicor's mid-term guidance/strategy


Capex for Property, plant and equipment



1) 2018: New plant in Romania, 2019: Paint-Shop and precision molding in Indonesia, 2022: New plant in Vietnam

- No capacity expansion in 2023
- Investment in PPE was in line with our expectations and support our further growth strategy
- Capex of 3% according our mid-term goals (excluding major footprint expansions)

Return on Invested Capital




- Strong ROIC progression in 2023 inline with mid-term guidance to be above 15%.
- ROIC improvement driven by
 - Revenue growth (24.5%)
 - profitability improvements (130 bps)
 - invested capital efficiency (treasury / ONWC improvement)
- Increase in ROIC compared to prior period as EBIT increased above invested capital.

ROIC in % = Core EBIT (EBIT before amortization of Intangible assets out of business combinations, 12m rolling) / Average Net Invested Capital (12m rolling)
 Average Net Invested Capital (12m rolling) = Equity plus Financial liabilities minus Intangible assets out of business combinations

Cicor has changed its accounting policy effective 1.1.2024 to offset Goodwill in equity at the time of acquisition with no amortization in future periods. All prior periods have been restated.

Long-term development of earnings per share



Cicor has changed its accounting policy effective 1.1.2024 to offset Goodwill in equity at the time of acquisition with no amortization in future periods. All prior periods have been restated.

- Underlying 2023 net earnings per share at CHF 4.19
- Underlying earnings exclude FX losses of CHF 4.1 million and one-off tax impacts of CHF 2.7 million (total EPS impact of CHF 1.54 ●)

Key Figures per Share

	2023	2022	Change %
Number of registered shares issued	3 411 169	3 409 542	+0.0%
Number of Treasury shares	- 249 404	- 241 916	+3.1%
Number of outstanding registered shares	3 161 765	3 167 626	-0.2%
Number of conditional shares for MCN	1 267 116	1 267 116	+0.0%
Number of outs. and cond. MCN shares	4 428 881	4 434 742	-0.1%
Average number of outst. and cond. MCN shares	4 428 767	3 719 122	+19.1%
Net profit (in TCHF)	11 760	9 178	+28.1%
Earnings per share (in CHF)	2.66	2.47	+7.6%
Share price (in CHF)	49.80	42.90	+16.1%
Market capitalization (in TCHF)	220 558	190 250	+15.9%

- The conversion of the MCN will result in 1,267,116 additional shares until 2027. These shares are considered outstanding for both EPS and market capitalization purposes.
- Optional conversion of the MCN started in January 2024
- Increase in average number of outstanding and conditional MCN shares from the issuance of the second tranche of MCNs in October 2022.
- Earnings per share increase driven by strong operating profitability.

Cicor has changed its accounting policy effective 1.1.2024 to offset Goodwill in equity at the time of acquisition with no amortization in future periods. All prior periods have been restated.

Two acquisitions successfully completed in 2023

Acquisitions

	PM	AFT	2023
Cash paid	23'498	1'368	24'866
Direct costs related to acquisition	421	157	578
Purchase consideration cash	23'919	1'525	25'444
less: Fair value of net assets acquired	-23'004	-1'313	-24'317
Goodwill	915	212	1'127
Non-current Assets	7'258	831	8'089
Current Assets	23'512	524	24'036
Non current liabilities	-348	0	-348
Current liabilities	-7'418	-41	-7'459
Total fair value of net assets acquired	23'004	1'313	24'317
Purchase consideration cash	23'919	1'525	25'444
less: cash and cash equivalents acquired	-3'459	0	-3'459
Cash outflow on acq. during the year	20'461	1'525	21'985

Cicor Digital Elektronik (PM)

- Two sites in Thuringia (Germany) and one site in Borj-Cedria (Tunisia)
- Closing of share deal in January 2023 for a consideration of TCHF 23 919, resulting in a Goodwill of TCHF 915
- Integrated in Cicor's EMS division

AFT Microwave (AFT)

- Cicor acquired the thin-film business of AFT microwave GmbH, Backnang (Germany), as part of an asset deal.
- Closing of deal in March 2023 for a consideration of TCHF 1 525, resulting in a Goodwill of TCHF 212.
- Integrated into Reinhardt Microtech GmbH, Ulm (Germany), which is part of the Cicor AS division

Outlook & Closing

Accelerated growth expected to continue in 2024

- **Order backlog** equivalent to almost one year's sales
- Important **new projects** are entering series production
- The **consolidation** of acquired companies will additionally lead to a significant increase in sales and earnings
- The **appreciation of the Swiss franc** against the euro and the US dollar, as well as a temporary **decline in demand** from customers in the smart building and other industrial sectors, will have a **dampening effect** on growth
- **Full year 2024 guidance** (Provided the geopolitical, economic and financial conditions do not deteriorate significantly):
 - Net sales of CHF 460 - 500 million
 - EBITDA margin in the target range of 10-13%



Continuing on the growth trajectory

Organic Growth	Revenue	Profitability	Other
7 - 10% p.A.	>600 million CHF⁴⁾	Core EBIT 7 – 10% EBITDA 10 – 13%	Core ROIC ¹⁾ >15% Net Debt / EBITDA <2.75 Capex ²⁾ up to 3%

- Cicor is well positioned to face economic headwinds due to its strategic markets being more resilient.
- Acquisitions will continue to play an important role as we see attractive opportunities with high returns.
- Dividends to be considered once Cicor delivering sustainable positive net cash flows.³⁾

1) Core ROIC in % = EBIT before amortization of intangible assets from acquisitions (12m rolling) / Average Net Invested Capital (12m rolling)

Average Net Invested Capital (12m rolling) = Equity plus Financial liabilities minus Intangible assets out of business combinations

2) CAPEX guidance expressed as % of revenue excluding major footprint expansions

3) Positive operating cash flows higher than negative investment cash flows (incl M&A) and financing cash flows (incl repayments) in at least two consecutive years.

4) The current mid-term guidance includes some moderate level of acquisitions.

Cicor – an asset for your portfolio

- **Market with resilient growth** driven by megatrends of electronification, outsourcing and nearshoring
- **Strategy targeting the most profitable segments of the market:** Industrial, Medical, Aerospace & Defense
- **Value accretive buy and build strategy** with disciplined approach and integration playbook
- **Management with track-record** for successful organic and inorganic growth



Agenda 2024

July 24	Interim Report 2024
---------	----------------------------

October 15	Business Update Q3/2024
------------	--------------------------------

September 18	Investora 2024 in Zurich
--------------	---------------------------------

September 23	Baader Investment Conference 2024 in Munich
--------------	--

November 25 - 27	Deutsches Eigenkapitalforum in Frankfurt
------------------	---

We plan to participate in various conferences and roadshows during 2024. As soon as the dates are confirmed, we will publish details on our website and in the SIX consolidated corporate calendar.



Analysts

Kepler Cheuvreux

Patrick Steiner
psteiner@keplercheuvreux.com
+43 (1) 20 577 383

Research Partners

Reto Huber
reto.huber@researchpartners.ch
+41 44 533 40 30

Zürcher Kantonalbank

Bernd Laux
bernd.laux@zkb.ch
+41 44 292 37 23

Baader Helvea

Zana Mamelli
zmamelli@helvea.com
+41 43 388 92 50

mwb Research

Alexander Zienkowicz
a.zienkowicz@mwb-research.com
+49 40 309 293 56

The latest list of analysts covering Cicor is available on our website: <https://www.cicor.com/en/investors/financial-information/analysts/>

Contacts



Alexander Hagemann
CEO



Peter Neumann
CFO



Michael Götti
VP Corporate
Marketing & Communications

Cicor Management AG, Gebenloostrasse 15, 9552 Bronschhofen, Switzerland
investor@cicor.com | +41 71 913 73 00

cicor

Thank you



cicor.com



Cicor Group



@cicor.group